Circulating free DNA as a prognostic biomarker in patients with advanced ALK+ NSCLC treated with alectinib from the global phase III ALEX trial.

Rafal Dziadziuszko,Solange Peters,Tony Mok,D. Ross Camidge,Johannes Noe,Malgorzata Nowicka,Walter Bordogna,Peter N. Morcos,Vlatka Smoljanovic,Alice T. Shaw

Circulating free DNA as a prognostic biomarker in patients with advanced ALK+ NSCLC treated with alectinib from the global phase III ALEX trial.

2019

Rafal Dziadziuszko
Solange Peters
Tony Mok
D. Ross Camidge
Johannes Noe
Malgorzata Nowicka
Walter Bordogna
Peter N. Morcos
Vlatka Smoljanovic
Alice T. Shaw

9053Background: Circulating free DNA (cfDNA) released predominantly by tumors into the blood correlates with tumor load, but correlation with outcomes after ALK inhibitor treatment is poorly unders...

Keywords:

Cancer research
Circulating free DNA
ALK inhibitor
Tumor Load
Pathology
Alectinib
Biomarker (medicine)
Medicine
prognostic biomarker
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations